<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548364</url>
  </required_header>
  <id_info>
    <org_study_id>FJD-VITDAMI-14-01</org_study_id>
    <nct_id>NCT02548364</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction (VITDAMI)</brief_title>
  <acronym>VITDAMI</acronym>
  <official_title>Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of calcifediol on left ventricular remodeling, mineral metabolism, plasma
      levels of several prognostic biomarkers and on endothelial function after an anterior
      myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac remodeling by MRI</measure>
    <time_frame>1 year</time_frame>
    <description>It is a composite outcome measure. It will be analyzed by measuring the following parameters: myocardium at risk, size of infarcted myocardium, saved myocardium, ejection fraction, left ventricular telesystolic and telediastolic volumes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic parameters</measure>
    <time_frame>1year</time_frame>
    <description>It is a composite outcome measure. It will be analyzed by measuring the following parameters: ventricular thickness and diameters, contractility abnormalities, ejection fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mineral metabolism parameters</measure>
    <time_frame>1 year</time_frame>
    <description>It is a composite outcome measure. It will be analyzed by measuring plasma levels of calcidiol, FGF-23, klotho, phosphate, and PTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prognostic biomarkers levels</measure>
    <time_frame>1 year</time_frame>
    <description>It is a composite outcome measure. It will be analyzed by measuring plasma levels of NT-proBNP, hsCRP, MCP-1 and galectin-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid levels</measure>
    <time_frame>1 year</time_frame>
    <description>It is a composite outcome measure. It will be analyzed by measuring plasma levels of TC, LDL, HDL, TG and non-HDL Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in flow mediated vasodilation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>1.5, 3, 6, 9, 12 and 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of treatment compliance</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Calcifediol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule with 15,690 IU p.o. every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule with placebo p.o. every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol</intervention_name>
    <description>calcifediol treatment</description>
    <arm_group_label>Calcifediol</arm_group_label>
    <other_name>vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo control group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 40 years and maximum 85 years.

          -  Anterior myocardial infarction

          -  Sign informed consent

        Exclusion Criteria:

          -  Death during the index event

          -  Age younger than 40 or older than 85 years

          -  Previous Infarction

          -  More than 7 days in hospitalization

          -  Systemic inflammatory or autoimmune disease

          -  Concomitant disorders limiting survival

          -  Concomitant cardiomyopathy

          -  Left ventricular hypertrophy &gt; 16mm in females and &gt; 17mm in males

          -  eGFR&lt;45

          -  LVEF&lt;30

          -  Incomplete revascularization

          -  Valvular prosthesis

          -  Aortic stenosis with mean gradient&gt; 25 mmHg

          -  Moderate or severe valvular regurgitation

          -  Hypersensitivity or intolerance vitamin D supplement o excipient

          -  Blood Calcium &gt;10.5 mg/dl

          -  Inability to follow.

          -  Difficulty in treatment compliance

          -  Contraindication for MRI, including indication to place a cardiac device

          -  Indication of therapy with vitamin D. Patient desires to take vitamin D.

          -  Drugs or conditions that interfere with the pharmacokinetics of calcifediol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSE TUÑON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IIS-FJD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Tuñón, MD</last_name>
    <phone>0034915504800</phone>
    <phone_ext>3701</phone_ext>
    <email>jtunon@fjd.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ALVARO ACEÑA, MD</last_name>
    <phone>0034915504800</phone>
    <phone_ext>3702</phone_ext>
    <email>aacena@fjd.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Cristobal, MD</last_name>
      <email>carmencristobalv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Manuel Escudier, MD</last_name>
      <email>jescudiervilla@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Rey Juan Carlos</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Sanz, MD</last_name>
      <email>petra.sanz@hospitalreyjuancarlos.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Móstoles</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nieves Tarin, MD</last_name>
      <email>nieves.tarin@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Valdemoro</city>
        <state>Madrid</state>
        <zip>28342</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Sanz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Tuñon, MD, PhD</last_name>
      <phone>915504800</phone>
      <phone_ext>3701</phone_ext>
      <email>jtunon@fjd.es</email>
    </contact>
    <contact_backup>
      <last_name>Raquel Muñoz, Pharmacy</last_name>
      <phone>+34 915504800</phone>
      <phone_ext>3214</phone_ext>
      <email>rmunozs@fjd.es</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Tuñon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alvaro Aceña Aceña, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Beltran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Ventricular remodeling</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

